Poorly differentiated neuroendocrine carcinoma is a rare malignancy that remains a challenge to treat. Poorly differentiatedneuroendocrine carcinoma occurs at an incidence of 2% annually in United States. The current standard of care is basedlargely upon retrospective data. There remains a need for large prospective cooperative group trials in the management ofpoorly differentiated neuroendocrine carcinoma. In this paper, we will review abstract #e15096 (Paclitaxel, carboplatin, andetoposide (TCE) in advanced poorly differentiated neuroendocrine carcinoma) by Loeffler et al. and #e15071 (Poorlydifferentiated neuroendocrine carcinoma (NEC G3): prognostic factors and potential novel targets) by Heetfeld et al.presented at the 2013 ASCO Annual Meeting highlighting treatment options in first and second lines for poorly differentiatedneuroendocrine carcinoma.
Muhammad Wasif Saif, Marvin Duque, Anumeha Gupta